A newly identified lipoprotein lipase (LPL) gene mutation (F270L) in a Japanese patient with familial LPL deficiency  by Takagi, Atsuko et al.
A newly identi¢ed lipoprotein lipase (LPL) gene mutation (F270L) in a
Japanese patient with familial LPL de¢ciency
Atsuko Takagi a, Yasuyuki Ikeda b;*, Eiji Takeda c, Akira Yamamoto d
a Department of Pharmacology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan
b Department of Etiology and Pathophysiology, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita,
Osaka 565-8565, Japan
c Department of Clinical Nutrition, School of Medicine, University of Tokushima, Tokushima 770, Japan
d Fourth Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
Received 14 April 2000; received in revised form 18 July 2000; accepted 25 July 2000
Abstract
We have systematically investigated the molecular defects resulting in a primary lipoprotein lipase (LPL) deficiency in a
Japanese male infant (proband SH) with fasting hyperchylomicronemia. Neither LPL activity nor immunoreactive LPL mass
was detected in pre- or postheparin plasma from proband SH. DNA sequence analysis of the LPL gene of proband SH
revealed homozygosity for a novel missense mutation of F270L (Phe270CLeu/TTT1065CTTG) in exon 6. The function of
the mutant F270L LPL was determined by both biochemical and immunocytochemical studies. In vitro expression
experiments on the mutant F270L LPL cDNA in COS-1 cells demonstrated that the mutant LPL protein was synthesized as
a catalytically inactive form and its total amount was almost equal to that of the normal LPL. Moreover, the synthesized
mutant LPL was non-releasable by heparin because the intracellular transport of the mutant LPL to the cell surface ^ by
which normal LPL becomes heparin-releasable ^ was impaired due to the abnormal structure of the mutant LPL protein.
These findings explain the failure to detect LPL activities and masses in pre- and postheparin plasma of the proband. The
mutant F270L allele generated an XcmI restriction enzyme site in exon 6 of the LPL gene. The carrier status of F270L in the
proband’s family members was examined by digestion with XcmI. The proband was ascertained to be homozygous for the
F270L mutation and his parents and sister were all heterozygous. The LPL activities and masses of the parents and the sister
(carriers) were half or less than half of the control values. Regarding the phenotype of the carriers, the mother with a sign of
hyperinsulinemia manifested hypertriglyceridemia (type IV hyperlipoproteinemia), whereas the healthy father and the sister
were normolipidemic. Hyperinsulinemia may be a strong determinant of hypertriglyceridemia in subjects with heterozygous
LPL deficiency. ß 2000 Elsevier Science B.V. All rights reserved.
0925-4439 / 00 / $ ^ see front matter ß 2000 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 0 0 ) 0 0 0 6 7 - 3
Abbreviations: LPL, lipoprotein lipase; VLDL, very low density lipoprotein; apo, apolipoprotein; HTGL, hepatic triglyceride lipase;
PHP, postheparin plasma; LDL, low density lipoprotein; HDL, high density lipoprotein; OGTT, oral glucose tolerance test; IDL,
intermediate density lipoprotein; SIIA, selective immunoinactivation assay; EIA, enzyme immunoassay; mAb, monoclonal antibody;
PCR-SSCP, polymerase chain reaction-single strand conformation polymorphism; RFLP, restriction fragment length polymorphism;
DMEM, Dulbecco’s modi¢ed Eagle’s medium; FCS, fetal calf serum; PBS, phosphate-bu¡ered saline; AEC, 3-amino-9-ethylcarbazole;
FP-IRI, fasting plasma-immunoreactive insulin; BMI, body mass index; FPG, fasting plasma glucose
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1. Introduction
Human lipoprotein lipase (LPL, EC 3.1.1.34) is a
glycoprotein enzyme with a molecular weight of
61 000 [1] that is synthesized by several cell types
including adipocytes [2]. Human LPL cDNA predicts
a translated molecular weight of 50 394 with 448 ami-
no acid residues for the mature form of the protein
in the absence of any sugar moiety [3]. The human
LPL gene, 30 kb in length, is located on chromosome
8p22 [4] and consists of ten exons [5^7]: exons 1^9
contain coding regions, whereas exon 10 contains a
3P-non-coding region. LPL is anchored on the cell
surface by a proteoglycan chain [8,9] and plays a
key role in hydrolyzing triglycerides in chylomicrons
and very low density lipoproteins (VLDL) at the ¢rst
step in their metabolism [10]. In this reaction, LPL
requires apolipoprotein (apo) C-II as an essential
cofactor and produces chylomicron and VLDL rem-
nants, thereby releasing free fatty acids which are
either used as energy or reesteri¢ed for endogenous
triglyceride storage in adipocytes. The resulting lipo-
protein remnants are thought to be further catabol-
ized by hepatic triglyceride lipase (HTGL) [11]. In
plasma (preheparin plasma), small amounts of LPL
and HTGL are detected as catalytically inactive
forms [12], whereas intravenous injection of heparin
releases signi¢cant amounts of both lipases into the
circulation in their catalytically active forms [12,13].
Plasma obtained after injection of heparin (post-
heparin plasma, PHP) is, in general, used as a clinical
sample for measuring LPL and HTGL activities and
immunoreactive masses [12^14].
Type I hyperlipoproteinemia is a rare autosomal
recessive disorder characterized by severe fasting hy-
pertriglyceridemia due to massive accumulation of
chylomicrons and normal or marginally increased
VLDL, and by decreased low density lipoprotein
(LDL) and high density lipoprotein (HDL) levels in
the plasma [14,15]. This disease often presents in in-
fancy or early childhood with episodes of abdominal
pain, pancreatitis, xanthomatosis, lipemia retinalis
and hepatosplenomegaly [14]. The disorder has
been reported to be caused mainly by primary LPL
de¢ciency, and by primary apo C-II de¢ciency, or a
circulating inhibitor for LPL [14]. Clinically, ¢rst
screening for primary LPL de¢ciency is performed
by analyzing the LPL activity [14] as well as the im-
munoreactive LPL mass [12,16] in PHP samples.
Subsequently, LPL gene analysis of subjects with
an LPL abnormality has been carried out, and ho-
mozygous or compound heterozygous LPL de¢-
ciency has been determined in subjects with type I
hyperlipoproteinemia. To date, over 60 distinct mu-
tations in the LPL gene, including gene rearrange-
ments, missense, nonsense and splice mutations,
have been identi¢ed and summarized in recent re-
views [14].
Early family studies on phenotypic expression of
heterozygous LPL-de¢cient subjects (heterozygous
carriers) showed a close relationship between the het-
erozygous carriers and mild hypertriglyceridemia
(type IV hyperlipoproteinemia), which is character-
ized by mild accumulation of serum triglycerides as a
consequence of an elevated VLDL concentration and
a normal level of LDL cholesterol [17^19]. Further-
more, as the reverse approach, a heterozygous LPL
gene mutation has been identi¢ed in a Japanese pa-
tient with type IV hyperlipoproteinemia [20]. In het-
erozygous carriers, analysis of possible factors lead-
ing to the expression of mild hypertriglyceridemia
revealed participation of factors such as age, obesity,
high alcohol intake and/or hyperinsulinemia [17,19^
23].
In the present paper we describe in detail a molec-
ular defect of LPL detected in a Japanese male infant
(proband SH) with type I hyperlipoproteinemia due
to primary LPL de¢ciency. He was a homozygote for
a novel missense mutation (F270L, Phe270CLeu/
TTT1065CTTG) of exon 6 in the LPL gene, which
was shown to result in the synthesis of catalytically
inactive LPL in an in vitro study of the expression of
the mutant F270L LPL cDNA in COS-1 cells. His
parents and sister were all heterozygous carriers of
the F270L allele, while only the mother, with hyper-
insulinemia, manifested hypertriglyceridemia (type
IV hyperlipoproteinemia).
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2. Materials and methods
2.1. Materials
Human LPL and human HTGL were puri¢ed
from PHP according to the methods described pre-
viously [1]. These puri¢ed human PHP-LPL and
PHP-HTGL were used as standard proteins for mea-
suring both proteins by a one-step sandwich-enzyme
immunoassay (EIA) procedure. Pure human PHP-
LPL (7.08 Wmol/h/ml; spec. act. 45 mmol/h/mg
[12]) was used as an enzyme source to check whether
or not the patient’s plasma contained functionally
active apo C-II or possible inhibitors of LPL. A
normal human LPL cDNA (HLC601; a 1612 bp
fragment consisting of nucleotides 32^1643 reported
by Wion et al. [3]) containing the complete coding
region of LPL was prepared from the human THP-I
(monocytic leukemia cell line) macrophage cDNA
library constructed in Vgt10 vector [24]. COS-1
cells (JCRB9082) were obtained from Japanese Can-
cer Research Resource Bank (Tokyo, Japan).
Rabbit anti-human PHP-LPL polyclonal antiserum,
prepared as previously reported [1], was utilized
to visualize LPL proteins expressed in COS-1
cells.
2.2. Subjects
A 1-month-old Japanese male (proband SH) was
admitted to the hospital of Tokushima University
because of a milky appearance of the fasting plasma.
His weight was 3880 g. Physical examination re-
vealed symptoms of eruptive xanthoma on the neck
and back, and lipemia retinalis, but no signi¢cant
hepato- or splenomegaly. The plasma concentrations
of triglycerides and total cholesterol were 8160 mg/dl
and 774 mg/dl, respectively (normal upper limits of
triglycerides and total cholesterol: 150 and 230
mg/dl, respectively). He was referred from the hospi-
tal of Tokushima University to our Institute (Na-
tional Cardiovascular Center Research Institute) to
examine the etiology of the underlying severe hyper-
triglyceridemia. A family history of consanguinity
was found: proband SH’s father and mother were
cousins. His family (H-family) members (father,
mother and sister) were also investigated. Ninety-
three healthy volunteers (49 males and 44 females),
aged between 23 and 69 years with a mean þ S.D. of
43.9 þ 13.1 years, were studied as a control group.
Their mean serum triglyceride and cholesterol con-
centrations were 86.8 þ 31.0 mg/dl and 195.5 þ 26.2
mg/dl (mean þ S.D.), respectively. Female subjects
(12 subjects) were selected from the 44 normal female
subjects as an age-adjusted control group. Four
healthy male volunteers with a mean þ S.D. of
2.1 þ 0.9 years were studied as a control group with
their parents’ agreement.
2.3. Laboratory and biochemical tests, and lifestyle
questionnaire
Blood samples were obtained after the subjects
had fasted overnight, and plasma and serum were
prepared. These samples were used for routine labo-
ratory tests for endocrinological disorders, liver dys-
function, renal disease, autoimmune disease, serum
lipids and apolipoproteins. In some cases, an oral
glucose tolerance test (OGTT) was performed with
a 75 g glucose load, and the sum of glucose and
insulin concentrations during the course of the
OGTT was calculated by integrating the 0, 30, 60,
90 and 120 min time points. Serum lipoproteins were
fractionated into ¢ve classes according to their
density by sequential £otation ultracentrifugation
[25]: chylomicron (d6 1.006 g/ml), VLDL (d6 1.006
g/ml), intermediate density lipoprotein (IDL, d =
1.006^1.019 g/ml), LDL (d = 1.019^1.063 g/ml) and
HDL (d = 1.063^1.21 g/ml). The triglyceride and
cholesterol concentrations of the serum and the frac-
tionated lipoproteins were measured by enzymatic
methods according to the suppliers’ directions (Tri-
glyceride G-test Wako, Wako Pure Chemical Indus-
tries, Osaka, Japan; Determiner TC5, Kowa Medex,
Tokyo, Japan). Apo A-I, A-II, B, C-II, C-III, and E
were measured by a single radial immunodi¡usion
assay (Daiichi Pure Chemicals, Tokyo, Japan) ac-
cording to the manufacturer’s directions. Apo E gen-
otype was determined by the method reported by
Hixson et al. [26].
Tobacco use and alcohol consumption were exam-
ined by a questionnaire. The kind of alcoholic bev-
erage, the quantity per day and the frequency per
week and month were asked. H-family members’ in-
takes of alcoholic beverages were shown as grams of
alcohol per day based on the values of 22 g of alco-
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hol per 633 ml of beer, 180 ml of sake and 70 ml of
whisky.
2.4. Assay of functional signi¢cance of apo C-II and
possible inhibitors for LPL in plasma
Plasma was obtained from the subjects after fast-
ing overnight and centrifuged at 356 000Ug for 2 h
using a Beckman TL-100 Ultracentrifuge to £oat tri-
glyceride-rich lipoproteins such as chylomicron and
VLDL which disturb apo C-II assay. After centrifu-
gation, the top triglyceride-rich lipoproteins were re-
moved and the ¢nal plasma volume was adjusted to
the original plasma volume. The triglyceride-rich
lipoprotein-depleted plasma (20 Wl) containing en-
dogenous plasma apo C-II was mixed well with 30
Wl of gum arabic-emulsi¢ed tri[9,10-3H]olein (20
Wmoles of triglyceride/ml; spec. act. 330.4 GBq/
mole) to prepare a substrate for LPL assay. Using
this substrate, the assay of the puri¢ed human PHP-
LPL (0.16 Wg of protein) was performed in a ¢nal
volume of 0.3 ml of 0.2 M Tris-HCl bu¡er (pH 8.5)
containing 5% bovine serum albumin and 0.15 M
NaCl, as described previously [1]. In the assay for
possible inhibitors of LPL in plasma, the triglycer-
ide-rich lipoprotein-depleted plasma (20 Wl) and 20 Wl
of the puri¢ed human PHP-LPL (8 Wg of protein/ml)
were mixed in a test tube and incubated for 1 h in an
ice bath. Then, the LPL activity was measured using
30 Wl of the gum arabic-emulsi¢ed tri[9,10-3H]olein
in the presence of pure apo C-II (1.7 WM) [1].
2.5. Measurement of LPL and HTGL activities and
immunoreactive masses in plasma
The subjects were fasted overnight, and blood
samples were collected in tubes containing 2Na-
EDTA (1 mg/ml) before and 10 min after the injec-
tion of heparin (30 units/kg body weight) for deter-
mination of the LPL and HTGL activities as well as
their masses. The LPL and HTGL activities in PHP
were measured with gum arabic-emulsi¢ed tri[9,10-
3H]olein (spec. act. 330.4 GBq/mole) as a substrate
by selective immunoinactivation assay (SIIA), as re-
ported previously [1,12]. Both enzyme activities were
expressed as Wmoles of free fatty acid released per
hour per ml of enzyme solution, unless otherwise
mentioned.
One-step sandwich-EIA for LPL mass quanti¢ca-
tion was performed using a Markit-F LPL kit (Dai-
nippon Pharmaceutical, Osaka, Japan) and the sand-
wich-EIA for HTGL mass quanti¢cation was also
carried out, as described previously [12]. The immu-
noreactive LPL and HTGL masses in preheparin
plasma and in PHP were measured and the incre-
ment in the LPL and HTGL masses was calculated
as the di¡erence between the masses in preheparin
plasma and PHP, respectively. The enzyme mass val-
ues were expressed as ng of LPL and HTGL/ml of
plasma, respectively.
2.6. DNA analysis
2.6.1. Genomic DNA extraction, Southern blot
analysis and polymerase chain reaction
(PCR)-single strand conformation
polymorphism (SSCP) analysis
Genomic DNA was isolated from the whole blood
of subjects, and it was subjected to Southern blot
analysis after digestion with the appropriate restric-
tion enzymes. Hybridization was performed using
32P-labeled HLC601 as a probe according to the
standard procedure [27]. The blotted sheets were ex-
posed to Kodak XOMAT AR ¢lm for several days
at 380‡C with intensifying screens. LPL gene aber-
rations were detected by the PCR-SSCP method, as
previously described [20]. SSCP analysis of the la-
beled DNA fragments ampli¢ed by PCR was carried
out by electrophoresis using 6% polyacrylamide gel
containing 10% glycerol, and the bands were visual-
ized by autoradiography.
2.6.2. Direct DNA sequencing
DNA fragments containing each of exons 1^9 were
enzymatically ampli¢ed and directly sequenced by
the previously described method [28]. DNA sequence
analysis was performed by the dideoxynucleotide
chain termination method of Sanger et al. [29] using
a Circum Vent Thermal Cycle Dideoxy DNA Se-
quencing Kit (New England BioLabs, Beverly, MA,
USA).
2.6.3. Restriction enzyme digestion of PCR-ampli¢ed
DNA
LPL gene exon 6 was ampli¢ed by PCR using the
exon-6F and -6R primer pair [20]. The ampli¢ed
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DNA was digested with one unit of XcmI restriction
enzyme (New England BioLabs) overnight at 37‡C.
The resulting DNA fragments were analyzed on 4%
NuSieve agarose gel (FMC BioProducts, Rockland,
ME, USA). DNA bands were visualized by staining
with ethidium bromide.
2.6.4. Haplotype analysis
The haplotype of the LPL gene was determined by
analysis of the restriction fragment length polymor-
phism (RFLP) using HindIII, PvuII and BamHI, and
tetrarepeat (TTTA) polymorphism at intron 6 [30] in
the LPL gene locus, as previously described [19,20].
2.6.5. Construction of site-directed mutagenized
LPL cDNA
Vgt10 vector containing the normal LPL cDNA
(HLC601) was digested with EcoRI. The EcoRI frag-
ment of the normal LPL cDNA was subcloned into
phagemid Bluescript SK II M13 (3) vector (Strata-
gene, La Jolla, CA, USA). Mutant F270L LPL
cDNA was generated from the normal LPL cDNA-
Bluescript SK II M13 (3) vector with a primer (No.
272) of 5P-AAGGAAGCCTTGGAGAAAGGGC-
TC-3P using a Mutan-K kit (site-directed mutagene-
sis system, Takara, Kyoto, Japan). The underlined
base on the primer was the mutant-speci¢c base.
The Bluescript vectors containing the normal LPL
cDNA and the mutant LPL cDNAs were digested
with NotI and ApaI restriction enzymes, and the di-
gested LPL cDNA fragments were subcloned into an
expression vector (pRc/CMV; Invitrogen, San Die-
go, CA, USA) with the cytomegalovirus early pro-
moter, respectively. These constructs were designated
as normal LPL cDNA-pRc/CMV and mutant F270L
LPL cDNA-pRc/CMV. DNA sequence analysis of
the constructs was performed with a Circum Vent
Thermal Cycle Dideoxy DNA Sequencing Kit.
2.7. Expression of the normal LPL- and the mutant
LPL-cDNAs in COS-1 cells, and LPL enzyme
assay
COS-1 cells (5U106 cells) were suspended in a to-
tal volume of 0.8 ml of potassium-phosphate-bu¡-
ered saline (30 mM NaCl, 120 mM KCl, 8.1 mM
Na2HPO4, 1.46 mM KH2PO4, 10 mM MgCl2) con-
taining 1 Wg of L-galactosidase expression plasmid
(pCH110, Pharmacia) and 20 Wg of the normal
LPL cDNA-pRc/CMV, the mutant F270L LPL
cDNA-pRc/CMV, or the expression vector of pRc/
CMV. The mixtures were transferred into a 0.4 cm
cuvette (Gene Pulser Cuvette, Bio-Rad, CA, USA),
respectively. The transfection was performed by an
electroporation method using Bio-Rad Gene Pulser
II as follows: cells were cooled in a cuvette on ice for
15 min, exposed to 220 V and 950 WFD, and stood
for 10 min at room temperature. The transfected
COS-1 cells were plated into 10 cm dishes containing
10 ml of Dulbecco’s modi¢ed Eagle’s medium
(DMEM, ICN Biomedicals Japan, Australia) supple-
mented with 10% heat-inactivated fetal calf serum
(FCS, Flow Laboratories, Australia), and cultured
for 2.5 days at 37‡C and 5% CO2. After 2.5 days
of culture, the medium was removed, and the cells
were washed three times with 5 ml of phosphate-
bu¡ered saline (PBS). The washed cells were treated
three times for 5 min at room temperature with 0.5
ml of DMEM containing 10% FCS and 5 units of
heparin (Novo Industry, Denmark) in order to re-
lease LPL bound to the cell surface. The pooled me-
dium (a total volume of 1.5 ml) was centrifuged at
4‡C for 10 min at 10 000Ug to remove insoluble
materials and the resulting supernatant containing
heparin-released LPL was immediately frozen by liq-
uid nitrogen, stored at 380‡C for determination of
LPL activity and immunoreactive LPL mass. The
remaining cells were washed three times with 5 ml
of PBS and harvested in 2.0 ml of Cell-Solubilizer
(20 mM sodium phosphate bu¡er, pH 7.4, containing
1 mM EDTA, 10% glycerol, 3 mM benzamidine,
3.1 WM aprotinin, heparin (10 units/ml) and 0.15%
Briji-35), and solubilized by 1 min of sonication us-
ing a Branson sonicator. The cell lysate was centri-
fuged at 4‡C for 10 min at 10 000Ug to remove cell
debris, £ash-frozen, and stored at 380‡C for deter-
mination of the intracellular LPL activity and mass.
The LPL activity and immunoreactive LPL mass
were determined as described above, and these values
were adjusted based on the L-galactosidase activity
co-expressed in COS-1 cells.
2.8. Immunocytochemical procedures
COS-1 cells (7.0U104 cells/dish) transfected with
the normal LPL cDNA-pRc/CMV were seeded into
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three dishes (A, B and C) and cultured for 3 days in
DMEM containing 10% FCS at 37‡C under the con-
dition of 5% CO2. Heparin treatment and cell har-
vest were carried out at 25‡C. After removal of the
culture medium, the dish (A) was treated for 5 min
with 1 ml of DMEM/10% FCS without heparin, and
the other two dishes (B and C) were treated for 5 min
with 1 ml of the same medium containing heparin
(10 units/ml). These treatments were repeated three
times in a total and the media were discarded. All the
treated cells were washed with PBS, ¢xed with a 10%
formalin neutral bu¡er solution (pH 7.4) (Wako Pure
Chemical Industries) for 30 min at 25‡C, and washed
with PBS. The two dishes (A and B) were further
treated for 30 min with 2 ml of PBS containing
0.3% H2O2 to detect LPL proteins bound to the
cell surface. The dish (C) was further treated for 30
min with 2 ml of methanol containing 0.3% H2O2 to
detect intracellular LPL proteins. COS-1 cells
(7.0U104 cells) transfected with the mutant F270L
LPL cDNA-pRc/CMV were seeded into three dishes
(D, E and F) and treated in the same way as in the
normal LPL experiment described above.
All six dishes (A, B, C, D, E and F) were washed
with PBS, and treated with 5% normal goat serum/
PBS solution for 20 min at 25‡C. The cells were
incubated for 1 h at 25‡C with rabbit anti-human
PHP-LPL polyclonal antiserum (1/1000) diluted
with 1.5% normal goat serum/PBS solution (dilution
bu¡er). After 1 h of incubation, the cells were incu-
bated for 0.5 h at 25‡C with 1 ml of biotinylated goat
anti-rabbit IgG (Vector Lab., Burlingame, CA, USA)
in the dilution bu¡er, reacted with 1 ml of avidin/
biotinylated horseradish peroxidase complexes (Vec-
tor Lab.) in the dilution bu¡er, and then stained for
20 min at 25‡C with 0.02% of 3-amino-9-ethylcarba-
zole (AEC)/0.01% H2O2 in 50 mM acetate bu¡er. In
control experiments, the cells were incubated with
non-immune rabbit serum (1/1000) dissolved in dilu-
tion bu¡er, followed by the procedures described
above. After the AEC reaction, nuclei were stained
with Mayer’s hemalum solution. Photographs were
taken using an Olympus (Vanox S) light microscope.
3. Results
3.1. Laboratory data of proband SH and treatment
At the age of 1 month proband SH exhibited an
extremely high triglyceride concentration of more
than 8000 mg/dl, which was 53 times higher than
the control (150 mg/dl). Analysis of serum lipids,
lipoproteins and apolipoproteins gave a typical phe-
notype expression of type I hyperlipoproteinemia as
evidenced by fasting hyperchylomicronemia with tri-
glycerides above 7000 mg/dl, and low cholesterol
concentrations of both LDL and HDL (Fig. 1). Pos-
Table 1
LPL and HTGL activities and immunoreactive masses in preheparin plasma and PHP of proband SH and his family members
Subject’s IDa Subject LPL HTGL
Activity
PHP (U)
Immunoreactive mass Activity
(U)
Immunoreactive mass
Preheparin
plasma
(ng/ml)
PHP
(ng/ml)
Incrementb
(ng/ml)
Preheparin
plasma
(ng/ml)
PHP
(ng/ml)
Incrementb
(ng/ml)
II-2 Proband SH NDc 11 11 0 27.5 34 1643 1609
I-1 Father TH 5.6 15 129 114 15.2 25 1051 1026
I-2 Mother TH 3.8 16 89 73 11.2 27 660 633
II-1 Sister CH 5.2 20 115 95 12.3 25 835 810
Normal (n = 93)
(mean þ S.D.)
9.8 þ 2.5 30 þ 9 216 þ 50 186 þ 46 22.5 þ 9 31 þ 11 1273 þ 517 1242 þ 517
The enzyme activities and immunoreactive masses were quanti¢ed by SIIA and sandwich-EIA, respectively. The unit (U) of activity is
de¢ned as Wmoles/h/ml, as described in Section 2.
aNumbers are the same as in Fig. 1.
bThe increment represents the di¡erence between the preheparin plasma and PHP immunoreactive masses.
cND, not detectable.
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sible factors such as apo C-II and apo E, leading to
fasting hyperchylomicronemia, were analyzed. The
serum concentration of apo C-II, which is an essen-
tial cofactor for activating LPL, was 6 times higher
than the normal range in proband SH due to the
accumulation of chylomicron particles. The biologi-
cal function of apo C-II was found to be normal
since proband SH’s plasma properly activated pure
human PHP-LPL in vitro (data not shown). The
genotype of apo E was E3/E4 (Fig. 1), which was
not associated with hyperchylomicronemia. To avoid
acute pancreatitis in proband SH, breast feeding was
stopped and alimentary treatment with a 900 kcal
diet consisting of milk containing medium chain tri-
glycerides was started after admission. The plasma
triglyceride concentration decreased to 1200 mg/dl
7 days after the alimentary treatment, and the symp-
toms of eruptive skin xanthoma and lipemia retinalis
disappeared.
Proband SH was maintained on a daily diet (300^
600 kcal) consisting primarily of carbohydrates and
amino acids, and fat with medium chain triglycerides
whose fat content was less than 10% of the total
calories. The plasma triglyceride level of the proband
was well controlled and kept at less than 1000 mg/dl
until 2.5 years old. Growth and development were
normal without any signi¢cant episode of acute pan-
creatitis until his present age of 8. At the age of
8 years, the serum lipids, lipoproteins and apolipo-
proteins were examined again (Fig. 1). The serum
triglyceride and cholesterol concentrations were
267 mg/dl and 101 mg/dl, respectively, indicating
that lipids were well controlled by the low fat diet
(less than 20 g of fat). The elevation of serum trigly-
cerides, which was 1.8 times higher than that of the
control, was due to accumulation of chylomicron
and VLDL triglycerides. The LDL and HDL choles-
terol concentrations were approximately half and
one-fourth of the control, respectively.
3.2. Analysis of LPL and HTGL activities and masses
in plasma of H-family members
Table 1 presents the data for the LPL and HTGL
activities and masses in the preheparin plasma and
PHP of H-family members and the normal control
subjects. Proband SH’s PHP lacked LPL activity,
and the increment in the LPL mass value (the di¡er-
ence between the preheparin plasma and PHP immu-
noreactive masses) was zero; proband SH was thus
diagnosed as having primary LPL de¢ciency. The
possible existence of plasma inhibitors of LPL was
excluded because his plasma did not inhibit pure
human PHP-LPL in vitro (data not shown). The
LPL activities and masses of his family members
were half or less than half of the mean control val-
ues, respectively. The HTGL activity and mass of the
Fig. 1. Proband SH and his family members’ clinical data. Pro-
band is indicated by the arrow. F, proband SH, a type I hyper-
lipoproteinemic subject who is homozygous for the mutant
F270L (LPLmima) allele, resulting in non-functional LPL; , ,
normolipidemic subjects who are heterozygous for the mutant
F270L allele; , a type IV hyperlipidemic subject, who is het-
erozygous for the mutant F270L allele; a, E, not studied; 2,
deceased subjects. ID, identi¢cation number; BMI, body mass
index; TG, triglycerides; CM, chylomicron; Chol, cholesterol;
FPG, fasting plasma glucose; FP-IRI, fasting plasma-immuno-
reactive insulin; OGT, oral glucose tolerance; ND, not detect-
able; 3, not tested; 4glucose and 4IRI are the sum of glucose
and insulin concentrations in plasma obtained at 0, 30, 60, 90
and 120 min during 75 g OGT test, respectively. Depictions of
the genotypes are derived from the results presented in Figs. 2
and 3.
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proband were slightly higher than that of the normal,
while those of other H-family members were within
the normal ranges.
3.3. Identi¢cation of LPL gene mutation site of
proband SH, and carrier status and haplotype of
the mutant allele in H-family
The gross structure of proband SH’s LPL gene
was examined by Southern blot analysis, and no ap-
preciable deletions or insertions in the LPL gene
were detected (data not shown). Each DNA segment
encompassing an exon and its £anking regions, and
the 5P-upstream region of the LPL gene were ampli-
¢ed by PCR and analyzed by the SSCP method. The
PCR-SSCP pattern of proband SH’s LPL gene exon
6 was di¡erent from the pattern of the normal sub-
jects (data not shown). Proband SH exhibited two
distinct SSCP bands from the variant alleles but no
SSCP bands from the normal alleles, suggesting that
proband SH carries a homozygous mutation in exon
6 of the LPL gene.
The mutation site in proband SH’s LPL gene exon
6 was determined by directly sequencing a DNA seg-
ment encompassing exon 6 and its £anking regions,
as shown in Fig. 2. As expected, only one apparent
nucleotide substitution was identi¢ed, at position
1065 of exon 6. Nucleotide T1065, at the third posi-
tion of the TTT codon coding for Phe270 in the nor-
mal allele, was substituted to G in the variant allele,
thereby generating a Leu codon (TTG) (Fig. 2). This
mutation (F270L) was designated as LPLmima on the
Fig. 2. Identi¢cation of the mutation site in LPL gene exon 6
of proband SH by the direct sequencing method. Nucleotide se-
quences of a part of the sense strand from exon 6 of proband
SH and a normal subject are shown. The substitution of nucle-
otide T1065, circled and indicated by an open triangle, to G1065,
circled and indicated by a solid triangle, is identi¢ed in exon 6
of the proband. This mutation replaces phenylalanine (Phe) at
residue 270 of the mature LPL with a leucine (Leu) (F270L al-
lele). Both the nucleotide sequence and the amino acid numbers
were taken from the human LPL cDNA sequence reported by
Wion et al. [3].
Fig. 3. Schematic illustration of a newly generated XcmI restric-
tion site in the mutant F270L LPL allele of proband SH (A)
and the H-family members’ carrier status for this mutation (B).
LPL gene exon 6 was ampli¢ed using an Exon-6F and -6R
primer pair by the PCR method. (A) The PCR-ampli¢ed DNA
fragments of the normal LPL allele produce a 341 bp band,
whereas those of the F270L LPL allele with a newly generated
XcmI site produce 159 bp and 182 bp bands by digestion with
the XcmI restriction enzyme. (B) The carrier status of the H-
family members for the F270L LPL allele was analyzed by 4%
NuSieve agarose gel electrophoresis after XcmI digestion of the
PCR-ampli¢ed DNA of each subject. DNA bands were visual-
ized by staining with ethidium bromide. Lanes: 1, normal sub-
ject (N); 2, father TH (F); 3, sister CH (S); 4, proband SH
(P); 5, mother TH (M); 6, xX174 DNA digested with HincII
as a size marker.
BBADIS 61981 24-10-00 Cyaan Magenta Geel Zwart
A. Takagi et al. / Biochimica et Biophysica Acta 1502 (2000) 433^446440
basis of the birthplace of proband SH. Furthermore,
other DNA segments encompassing exons and its
£anking regions were analyzed by the direct sequenc-
ing method, but no abnormalities were detected.
The F270L allele resulted in generation of an XcmI
restriction enzyme recognition site (Fig. 3A). Thus,
the carrier status of H-family members for the F270L
allele was examined by XcmI digestion of PCR-am-
pli¢ed DNA from the LPL gene exon 6. As shown in
Fig. 3B, proband SH was ascertained to be homozy-
gous for the F270L allele by detecting two distinct
bands (159 and 182 bp fragments) from the F270L
allele (lane 4). Father TH (lane 2), sister CH (lane 3)
and mother TH (lane 5) were all heterozygous for the
F270L allele, since they exhibited three distinct bands
of a 341 bp fragment from the normal allele, and 159
and 182 bp fragments from the F270L allele.
The haplotype of the F270L allele of proband SH
was determined by analyzing three RFLPs using
PvuII, HindIII and BamHI, and tetrarepeat
(TTTA) polymorphism at intron 6 of the LPL
gene. Analysis of the three RFLPs and the TTTA
polymorphism indicated a homozygous state of
(3)/(3) for PvuII, (+)/(+) for HindIII, (3)/(3) for
BamHI, and (ten)/(ten) repeats for TTTA, where (3)
and (+) mean that the DNA is ‘not digested’ and
‘digested’ by the enzymes, respectively (data not
shown). As a result, the haplotype of the F270L al-
lele of the proband was determined to be PvuII (3),
HindIII (+), BamHI (3) and ten repeats of TTTA.
The haplotypes of the F270L allele of the father,
sister and mother were all con¢rmed to be the
same as that of proband SH by testing for the three
RFLPs and TTTA polymorphism. The normal al-
leles of the parents and sister were all PvuII (+),
HindIII (+), BamHI (3) and ten repeats of TTTA.
3.4. Functional assay and intracellular location of
mutant F270L LPL expressed in COS-1 cells
The functional signi¢cance of the F270L LPL mu-
tation was examined by analyzing the LPL activity
and immunoreactive LPL mass expressed in COS-1
cells transfected with the mutant F270L LPL cDNA
in comparison with those expressed in COS-1 cells
transfected with the normal LPL cDNA. As shown
in Table 2, mutant F270L LPL protein was synthe-
sized almost equally with normal LPL in COS-1 cells
(441 þ 91 ng versus 474 þ 91 ng), whereas the mutant
F270L LPL activity was not detectable and the nor-
mal LPL activity was 8.3 þ 1.5 U. The normal LPL
activity was recovered by 63% in a medium contain-
ing LPL released by heparin and by 37% in cells after
heparin treatment, while the normal LPL protein was
recovered by 44% in the medium and by 56% in the
cells. Interestingly, speci¢c activity (the ratio of ac-
tivity/protein) of the normal LPL released by heparin
was about 2 times higher than that of LPL remained
Table 2
LPL activity and immunoreactive LPL mass expressed in COS-1 cells transfected with normal LPL cDNA and mutant F270L LPL
cDNA
cDNA Medium containing LPL
released by heparin
LPL in the cell lysate after
heparin treatment
Total LPL activity
(U)
Total LPL mass
(ng)
Activity
(U)
Mass
(ng)
S.A.a
(U/Wg)
Activity
(U)
Mass
(ng)
S.A.a
(U/Wg)
Normal LPL cDNA 5.2 þ 0.6 208 þ 5 25 þ 2 3.1 þ 1.0 267 þ 89 12 þ 1 8.3 þ 1.5 474 þ 91
Mutant F270L LPL
cDNA
NDb 13 þ 12 NDb 428 þ 80 NDb 441 þ 91
The enzyme activity and immunoreactive mass in the medium (1.5 ml) and the cell lysate (2.0 ml) were quanti¢ed by SIIA and sand-
wich-EIA, respectively. The unit (U) of activity is de¢ned as Wmoles/h/1.5 ml for the medium and Wmoles/h/2.0 ml for the cell lysate,
and the mass value is de¢ned as ng/1.5 ml for the medium and ng/2.0 ml for the cell lysate. The LPL activity and mass values were
corrected for di¡erences in transfection e⁄ciency determined by the L-galactosidase activity co-expressed in COS-1 cells. Total LPL
activity is the sum of the activities in the medium and the cell lysate, and total LPL mass is the sum of the masses in the medium
and the cell lysate. Each experiment was performed using four distinct dishes, and both the activity and mass values are shown as the
mean þ S.D.
aS.A., speci¢c activity; calculated by dividing the LPL activity by the LPL mass.
bND, not detectable.
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in the cells, suggesting that the LPL released by hep-
arin is a mature form and the LPL proteins in the
cells contain some premature LPL proteins, which
are catalytically inactive. In contrast, only 3% of
the mutant F270L LPL protein was released in the
medium by heparin and the remaining LPL protein
was in the cells.
The cellular locations of the normal LPL and the
mutant F270L LPL expressed in COS-1 cells were
further examined by immunocytochemical methods.
Detection of LPL protein bound to the cell surface
was carried out by ¢xing the cells with a 10% formal-
in solution in the absence of heparin, as described in
Section 2. LPL protein bound to the cell surface of
Fig. 4. Immunocytochemical detection of LPL proteins expressed in COS-1 cells transfected with the normal LPL cDNA and the mu-
tant F270L LPL cDNA. COS-1 cells expressing the normal LPL (A^C) and the mutant F270L LPL (D^F) were treated in the pres-
ence and absence of heparin and ¢xed with 10% formalin and/or methanol, and LPL proteins were immunostained, as described in
Section 2. (A) Normal LPL proteins, bound to the cell surface, stained under the conditions of no heparin treatment and ¢xation
with 10% formalin without methanol; (B) normal LPL proteins, bound to the cell surface, stained under the conditions of heparin
treatment and ¢xation with 10% formalin without methanol; (C) normal LPL proteins in the cells stained under the conditions of
heparin treatment and ¢xation with 10% formalin with methanol; (D) F270L LPL proteins, bound to the cell surface, stained under
the conditions of no heparin treatment and ¢xation with 10% formalin without methanol; (E) F270L LPL proteins, bound to the cell
surface, stained under the conditions of heparin treatment and ¢xation with 10% formalin without methanol; (F) F270L LPL proteins
in the cells stained under the conditions of heparin treatment and ¢xation with 10% formalin with methanol.
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the normal LPL-expressing COS-1 cells was clearly
stained (Fig. 4A), indicating that some of the synthe-
sized normal LPL protein was translocated to the cell
surface. In contrast, no LPL protein was detected on
the cell surface of the mutant F270L LPL-expressing
COS-1 cells (Fig. 4D). In order to examine whether
or not LPL protein is released from the cell surface,
both the normal LPL- and the mutant LPL-express-
ing COS-1 cells were treated with heparin, ¢xed with
a 10% formalin solution, and stained for LPL pro-
tein. No LPL protein was detected on the normal
LPL-expressing cells (Fig. 4B), indicating that nor-
mal LPL protein bound to the cell surface was able
to be released by heparin. In the case of the mutant
F270L LPL-expressing cells, essentially no LPL pro-
tein was observed after treatment with heparin (Fig.
4E). After heparin release of LPL protein bound to
the cell surface, the normal LPL- and the mutant
F270L LPL-expressing cells were ¢xed with both
10% formalin and a methanol solution so as to detect
intracellular LPL protein. LPL protein of the normal
LPL-expressing cells was well stained and distributed
throughout the cells (Fig. 4C), whereas LPL protein
in the mutant F270L LPL-expressing cells was local-
ized mainly in the perinuclear area of the cells (Fig.
4F).
Biochemical and immunocytochemical studies in-
dicate that the mutant F270L LPL protein is synthe-
sized as a catalytically inactive form in almost the
same amount as the normal LPL protein, but the
synthesized F270L LPL protein is not adequately
transported to the cell surface due to the abnormal
structure of the F270L LPL protein.
3.5. Phenotypic expression of heterozygous carriers of
the F270L allele in H-family
In H-family, proband’s father (42 years old), sister
(11 years old) and mother (39 years old) were all
heterozygous for the F270L allele (carriers of
F270L) (Fig. 3B). They showed about half or less
than half of the control LPL activity and mass levels
(Table 1). The phenotypic expression was examined
in order to elucidate correlations between heterozy-
gous LPL de¢ciency and factors leading to the ex-
pression of hypertriglyceridemia. Their clinical data
are listed in Fig. 1.
The mother manifested mild hypertriglyceridemia
(type IV hyperlipoproteinemia), as evidenced by a
fasting serum triglyceride values exceeding the upper
limit of 150 mg of triglyceride/dl of serum and a
normal level of serum cholesterol due to the accumu-
lation of VLDL particles secreted from the liver.
Factors possibly a¡ecting the catabolism of VLDL
were examined in addition to anomalous LPL, but
no signi¢cant factors were detected. This is, the apo
C-II level was normal and functionally active, the
apo C-II/C-III ratio was normal, and the apo E gen-
otype was E4/E4, by which the VLDL triglyceride
level is not a¡ected. When factors related to over-
production of VLDL in the liver were examined,
one factor, hyperinsulinemia, was noted. That is,
fasting plasma-immunoreactive insulin (FP-IRI)
and 4IRI (the sum of ¢ve points of IRI values mea-
sured at 0, 30, 60, 90, and 120 min after a 75 g
glucose load) were two-fold higher than normal,
whereas her body mass index (BMI) and fasting plas-
ma glucose (FPG) were normal. She did not have
liver or kidney disease or a history of smoking or
alcohol consumption.
In contrast, both the father and the sister were
normolipidemic, as evidenced by serum triglyceride
and cholesterol concentrations below the upper limit
of 150 mg/dl for triglycerides and 230 mg/dl for cho-
lesterol, respectively. Their apo C-II levels and func-
tions were normal, while the genotype of apo E was
E3/3 in the father, i.e., the normal type, and E3/4 in
the sister, in which the serum triglyceride level is not
a¡ected. They showed normal levels for the BMI,
FPG and FP-IRI. Also, they exhibited no clear evi-
dence of diabetes mellitus, obesity, liver disease or
renal failure. The father was a non-smoker and light
drinker (12 g of alcohol per day).
4. Discussion
We have systematically studied the molecular basis
of primary LPL de¢ciency in a 1-month-old Japanese
male (proband SH) with type I hyperlipoproteinemia
by analyzing the LPL activity and immunoreactive
LPL mass in preheparin plasma and PHP, and ana-
lyzing the genetic defect in the LPL gene. The pro-
band was a homozygote for a novel missense muta-
tion (F270L) which resulted in substitution of Phe270
(TTT1065) to Leu (TTG) due to a T to G single-base
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transversion at nucleotide position 1065 in exon 6.
The mutant F270L allele generated a new XcmI re-
striction enzyme site in exon 6 of the LPL gene, and
homozygosity of the F270L allele in the proband was
ascertained by digestion of the PCR-ampli¢ed LPL
gene exon 6 with XcmI enzyme. The functional sig-
ni¢cance of the mutant F270L LPL was examined by
in vitro expression studies of the F270L LPL cDNA
in COS-1 cells. The in vitro expression studies dem-
onstrated that the mutant F270L LPL was a catalyti-
cally inactive enzyme and accumulated in the perinu-
clear area (probably, the area of the rough
endoplasmic reticulum) of COS-1 cells due to an im-
pairment of intracellular transport of the enzyme to
the cell surface caused by the abnormal structure of
the mutant LPL protein. Thus, the mutant F270L
LPL molecules expressed in COS-1 cells were not
able to be released by heparin treatment. These
data readily explain why no LPL activity or immu-
noreactive LPL mass was detected in the PHP of
proband SH.
The catalytic and intracellular transport defects
underlying the mutant F270L LPL might be ex-
plained by elucidation of the superimpositional struc-
ture between the three-dimensional crystallographic
structure of human pancreatic lipase and human
LPL [31]. That study predicted that human LPL is
organized into two distinct regions, consisting of a
larger amino (N)-terminal domain (residues 1^312,
derived from exons 1^6) and a smaller carboxyl
(C)-terminal domain (residues 313^448, derived
from exons 7^9). Based on the predicted LPL struc-
ture, the LPL structure-function relationship has
been examined by analysis of the relationship be-
tween human LPL gene defects and its functional
abnormality, and also the functional signi¢cance of
site-directed mutagenized LPL [32]. Normal LPL re-
quires multiple functional regions to express its hy-
drolytic activity on triglycerides in chylomicron and
VLDL. The N-terminal domain of LPL includes the
catalytic triad residues (Ser132, Asp156 and His241),
the lid (residues 216^239) covering the catalytic triad,
heparin-binding and apo C-II-binding sites [32],
while the C-terminal domain contains the substrate-
binding [32] and heparin-binding regions [33]. Both
domains are connected by a £exible peptide (hinge
region), which plays an important role in changing
the sophisticated conformation between the N- and
C-terminal domains required for expressing lipase
activity, as demonstrated for human pancreatic lipase
[34]. Based on that study [34], the mutation site of
our identi¢ed mutant F270L LPL appears to be lo-
calized in the hinge region of the human LPL mole-
cule. Also, residues 266^285 (20 sequences of SKEA-
FEKGLCLSCRKNRCNN), including Phe270
(indicated by the underline), are fully conserved for
LPL in man, cattle, mice and guinea pigs [35]. Thus,
the substitution of Phe270 to Leu in the hinge region
may a¡ect the formation and/or stability of the re-
quired conformational change between the N- and
the C-domains, thereby resulting in a catalytically
inactive enzyme. Additionally, such an abnormal
conformational change of the F270L LPL may result
in impairment of its intracellular transport to the cell
surface, by which the LPL molecule becomes hepa-
rin-releasable.
Among the heterozygous carriers of the F270L
alleles in this study, only the proband’s mother (39
years old) manifested type IV hyperlipoproteinemia,
characterized by hypertriglyceridemia due to mild
accumulation of VLDL with a normal serum choles-
terol level. She did not show factors possibly a¡ect-
ing the catabolism of VLDL except for heterozygous
LPL de¢ciency. As factors possibly related to over-
production of VLDL in the liver, she showed a sign
of hyperinsulinemia with normal glucose tolerance
(normoglycemia). Hyperinsulinemia is known to be
a marker of resistance to insulin’s e¡ect on glucose
metabolism (insulin resistance): persons with normo-
glycemia but insulin resistance compensate for their
insulin resistance by secreting increased amounts of
insulin, resulting in hyperinsulinemia [36,37]. Thus,
compensatory hyperinsulinemia as a consequence of
insulin resistance appears to be a strong determinant
for hypertriglyceridemia in the mother with hetero-
zygous LPL de¢ciency. The expression of hypertri-
glyceridemia can be explained as follows. In insulin-
resistant states, insulin’s antilipolysis of endogenous
triglycerides in visceral adipose tissue is disturbed,
resulting in increased £ux of free fatty acids to the
liver and overproduction of VLDL in the liver due to
incorporation of an excess amount of free fatty acids
[38,39]. In the liver, the e¡ect of insulin in suppress-
ing the secretion of VLDL synthesized in the liver
into the circulation is impaired due to insulin resis-
tance, thereby leading to elevation of circulating tri-
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glyceride-enriched VLDL particles [40]. A half-nor-
mal amount of LPL due to heterozygous LPL de¢-
ciency is not enough to normalize the plasma tri-
glyceride level by hydrolyzing triglycerides in the
overproduced VLDL, resulting in hypertriglyceride-
mia.
This novel missense mutation (F270L) of the LPL
gene caused impairment of catalytic function and
resulted in accumulation of LPL protein in the peri-
nuclear area of the cells due to an abnormal struc-
ture. The impairment of the transport of the mutant
LPL to the cell surface due to its abnormal structure
might be explained by quality control in the endo-
plasmic reticulum [41]. This mutation might give an
information for further investigating the LPL struc-
ture-function relationship on the hinge region be-
tween the N- and C-terminal domains. Also, this
mutation is surmised to be useful for identifying ho-
mozygous LPL de¢ciency as well as heterozygous
LPL de¢ciency in unrelated subjects with primary
type IV hyperlipoproteinemia in order to gain further
understanding of the association between hetero-
zygous LPL de¢ciency and triglyceride synthesis-
stimulating factors.
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